A Landmark Gathering to Advance Precision Oncology and Biomarker Research for Prostate and Bladder Cancer

The BRECISE project, an EU-funded initiative under the Innovative Health Initiative (IHI), is holding its first face-to-face kick-off meeting on March 20-21, 2025, in Madrid, Spain. This meeting marks a key milestone in the five-year research initiative aimed at accelerating the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality AI biomarkers for prostate and bladder cancer.

The event brings together leading academic institutions, healthcare providers, industry partners, and regulatory experts to align strategies for implementing biomarker-driven approaches in diagnosis, disease progression monitoring, and treatment response assessment. Discussions are focused on work package updates, clinical study planning, regulatory compliance, and engagement with healthcare stakeholders.

BRECISE addresses critical gaps in oncology precision medicine, particularly in prostate and bladder cancer, by improving patient risk stratification, treatment optimization, and personalized therapeutic decision-making. The project’s approach integrates cutting-edge technologies such as AI-driven biomarker models, ex vivo drug testing, and digital health frameworks, ensuring the acceleration of biomarker adoption into clinical practice.

This kick-off meeting, strategically aligned with the European Association of Urology (EAU) Congress, reinforces the project’s commitment to collaborative research, policy alignment, and regulatory readiness in compliance with the European Health Data Space (EHDS), Artificial Intelligence Act, and Medical Device Regulation (MDR).

For further details, read the full press release below: